In syngeneic mouse tumor models resistant to anti-PD-L1 therapy, IFN-α full-scale IgG-fusion protein infusions, in contrast to IFN-α alone, were tolerated well and were capable of three-fold tumor volume reduction compared to the control group [111]. This evidence concerns the gene IFNA2 and neoplasm.